BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis of epilepsy.
Epilepsy is a serious neurological condition that affects almost 1% of the population at some period during their lives.
BioEP is a seizure susceptibility assessment technology that can enabling faster and more accurate diagnosis of epilepsy.
Neuronostics is now encouraging enquiries from Pharmaceutical companies, EEG hardware and software companies.
Neuronostics is a newly established University of Exeter (UK) spin-out, focused on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.
Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.
We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.
Thanks to everyone that attended our first online forum yesterday on #purpleday! We hosted over 50 people from around the world, with representatives from Africa, America, Asia, Australia and Europe! The focus... [Read More]
On Thursday 26th May, 3pm UK time (11am EDT), we’ll host an online event discussing how technology can help support those living with epilepsy . During this period of enforced distancing due... [Read More]
In recognition of our research links with the Cornwall Partnership NHS Foundation Trust (CFT), Dr Leandro Junges has been invited to give a talk at the CFT’s showcase event on 11 March... [Read More]